- Home
- IMMP vs NMRA Comparison
IMMP vs NMRA Comparison
Compare IMMP & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- NMRA
- Stock Information
- Founded
- IMMP 1987
- NMRA 2019
- Country
- IMMP Australia
- NMRA United States
- Employees
- IMMP N/A
- NMRA N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- NMRA
- Sector
- IMMP Health Care
- NMRA
- Exchange
- IMMP Nasdaq
- NMRA Nasdaq
- Market Cap
- IMMP 251.8M
- NMRA 268.5M
- IPO Year
- IMMP N/A
- NMRA 2023
- Fundamental
- Price
- IMMP $1.97
- NMRA $1.92
- Analyst Decision
- IMMP Buy
- NMRA Hold
- Analyst Count
- IMMP 1
- NMRA 8
- Target Price
- IMMP $7.00
- NMRA $5.83
- AVG Volume (30 Days)
- IMMP 120.6K
- NMRA 510.5K
- Earning Date
- IMMP 10-10-2025
- NMRA 11-11-2025
- Dividend Yield
- IMMP N/A
- NMRA N/A
- EPS Growth
- IMMP N/A
- NMRA N/A
- EPS
- IMMP N/A
- NMRA N/A
- Revenue
- IMMP $3,306,742.00
- NMRA N/A
- Revenue This Year
- IMMP $16.82
- NMRA N/A
- Revenue Next Year
- IMMP N/A
- NMRA N/A
- P/E Ratio
- IMMP N/A
- NMRA N/A
- Revenue Growth
- IMMP 31.28
- NMRA N/A
- 52 Week Low
- IMMP $1.32
- NMRA $0.61
- 52 Week High
- IMMP $2.71
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- IMMP 63.51
- NMRA 58.11
- Support Level
- IMMP $1.75
- NMRA $1.70
- Resistance Level
- IMMP $2.10
- NMRA $2.02
- Average True Range (ATR)
- IMMP 0.09
- NMRA 0.13
- MACD
- IMMP 0.03
- NMRA 0.01
- Stochastic Oscillator
- IMMP 74.79
- NMRA 67.14
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.